Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β | Science Translational Medicine

Skip to main content

Article Information

vol. 10 no. 424

DOI:

https://doi.org/10.1126/scitranslmed.aan5488

PubMed:

Published By:

American Association for the Advancement of Science

Print ISSN:

Online ISSN:

History:

Received for publication May 2, 2017
Resubmitted October 4, 2017
Accepted for publication November 13, 2017

Copyright & Usage:

Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works http://www.sciencemag.org/about/science-licenses-journal-article-reuseThis is an article distributed under the terms of the Science Journals Default License.

Author Information

Yan Lan*,
Dong Zhang,
Chunxiao Xu,
Kenneth W. Hance†,
Bo Marelli,
Jin Qi,
Huakui Yu,
Guozhong Qin,
Aroop Sircar,
Vivian M. Hernández,
Molly H. Jenkins,
Rachel E. Fontana,
Amit Deshpande,
George Locke,
Helen Sabzevari‡,
Laszlo Radvanyi and
Kin-Ming Lo*

EMD Serono Research and Development Institute Inc., Billerica, MA 01821, USA.

↵*Corresponding author. Email: yan.lan{at}emdserono.com (Y.L.); kinming.lo{at}emdserono.com (K.-M.L.)

↵† Present address: GlaxoSmithKline, Collegeville, PA 19426, USA.
↵‡ Present address: Intrexon Corporation, Germantown, MD 20876, USA.

Altmetric

Article usage

Article usage: January 2018 to May 2019

	Abstract	Full	Pdf
Jan 2018	7373	517	1228
Feb 2018	1280	155	351
Mar 2018	1216	189	410
Apr 2018	769	93	241
May 2018	1292	136	312
Jun 2018	935	146	207
Jul 2018	602	99	146
Aug 2018	440	202	160
Sep 2018	361	137	109
Oct 2018	429	165	165
Nov 2018	519	163	153
Dec 2018	380	110	108
Jan 2019	185	270	259
Feb 2019	61	772	774
Mar 2019	38	452	520
Apr 2019	19	381	400
May 2019	47	244	303

Science Translational Medicine: 10 (424)

Science Translational Medicine

Vol 10, Issue 424
17 January 2018

Table of Contents

Article Tools

Email

Thank you for your interest in spreading the word about Science Translational Medicine.
NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email

Your Name

Send To
Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

Message Subject (Your Name) has forwarded a page to you from Science Translational Medicine

Message Body (Your Name) thought you would like to see this page from the Science Translational Medicine web site.

Your Personal Message
Download Powerpoint
Print
Save to my folders

Log In with your AAAS Login
Alerts

Please log in to add an alert for this article.

Log In with your AAAS Login

Sign In to Email Alerts with your Email Address
Email
Citation tools
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

By Yan Lan, Dong Zhang, Chunxiao Xu, Kenneth W. Hance, Bo Marelli, Jin Qi, Huakui Yu, Guozhong Qin, Aroop Sircar, Vivian M. Hernández, Molly H. Jenkins, Rachel E. Fontana, Amit Deshpande, George Locke, Helen Sabzevari, Laszlo Radvanyi, Kin-Ming Lo

Science Translational Medicine17 Jan 2018

Blockade of PD-L1 and TGF-β pathways with M7824 activates effective innate and adaptive antitumor immune responses.

Citation Manager Formats

BibTeX

Bookends

EasyBib

EndNote (tagged)

EndNote 8 (xml)

Medlars

Mendeley

Papers

RefWorks Tagged

Ref Manager

RIS

Zotero
Share

Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

By Yan Lan, Dong Zhang, Chunxiao Xu, Kenneth W. Hance, Bo Marelli, Jin Qi, Huakui Yu, Guozhong Qin, Aroop Sircar, Vivian M. Hernández, Molly H. Jenkins, Rachel E. Fontana, Amit Deshpande, George Locke, Helen Sabzevari, Laszlo Radvanyi, Kin-Ming Lo

Science Translational Medicine17 Jan 2018

Blockade of PD-L1 and TGF-β pathways with M7824 activates effective innate and adaptive antitumor immune responses.

Share This Article:

Citing Articles in: